Advertisement

Safety and efficacy of erythropoiesis-stimulating agents in critically ill patients admitted to the intensive care unit: a systematic review and meta-analysis

  • Edward LittonEmail author
  • Peter Latham
  • Julia Inman
  • Jingjing Luo
  • Peter Allan
Systematic Review

Abstract

Purpose

Severe immune dysregulation is common in patients admitted to the intensive care unit (ICU) and is associated with adverse outcomes. Erythropoietin-stimulating agents (ESAs) have immune-modulating and anti-apoptotic effects. However, their safety and efficacy in critically ill patients remain uncertain. We evaluated whether ESAs, administered to critically unwell adult patients admitted to the ICU, reduced mortality at hospital discharge.

Methods

The search strategy was conducted according to a predetermined protocol and included OVID MEDLINE, OVID EMBASE and The Cochrane Central Register of Controlled Trials from inception until 20 May 2019. Publications were eligible for inclusion if they were randomized controlled trials (RCTs) including adult patients admitted to an ICU, that identified and reported a group receiving ESA therapy compared to a group not receiving ESA therapy and reported mortality. There were no language restrictions.

Results

The systematic review included 21 studies with 5452 participants. In-hospital mortality, reported in 16 studies of which only one was at low risk of bias, was lower in the ESA group (276 of 2187 patients, 12.6%) than the comparator group (339 out of 2204 patients, 15.4%), [relative risk (RR) 0.82, 95% CI 0.71–0.94, P = 0.006, I2 = 0.0%]. The RR of SAEs and thromboembolic events for the ESA and comparator groups were similar, RR 1.11 (95% CI 0.94–1.31, P = 0.228, I2 66%) and 1.22 (95% CI 0.95–1.58, P = 0.086, I2 47%), respectively.

Conclusions

In heterogenous populations of critically ill adults, evidence from RCTs of mainly low or unclear quality, suggests that ESA therapy may decrease mortality.

Keywords

Erythropoiesis-stimulating agents Critical care Immunomodulation 

Notes

Acknowledgements

The investigators would like to thank all the authors of the primary research material and in particular Profs Nichol, Robertson and Silver who provided additional data or clarification of their work. The authors would also like to thank the South Metropolitan Health Service Library and Information Service for their assistance and advice. Edward Litton is supported by a National Health and Medical Research Foundation Early Career Fellowship. This work was not supported by any other funding.

Compliance with ethical standards

Conflicts of interest

The authors declare no conflict of interests in relation to this manuscript.

Supplementary material

134_2019_5686_MOESM1_ESM.doc (5.1 mb)
Supplementary material 1 (DOC 5250 kb)
134_2019_5686_MOESM2_ESM.doc (56 kb)
Supplementary material 2 (DOC 55 kb)

References

  1. 1.
    Muszynski JA, Thakkar R, Hall MW (2016) Inflammation and innate immune function in critical illness. Curr Opin Pediatr 28:267–273CrossRefGoogle Scholar
  2. 2.
    Nairz M, Sonnweber T, Schroll A, Theurl I, Weiss G (2012) The pleiotropic effects of erythropoietin in infection and inflammation. Microbes Infect 14:238–246CrossRefGoogle Scholar
  3. 3.
    DeAngelo AJ, Bell DG, Quinn MW, Long DE, Ouellette DR (2005) Erythropoietin response in critically ill mechanically ventilated patients: a prospective observational study. Crit Care 9:R172–176CrossRefGoogle Scholar
  4. 4.
    Krafte-Jacobs B, Levetown ML, Bray GL, Ruttimann UE, Pollack MM (1994) Erythropoietin response to critical illness. Crit Care Med 22:821–826CrossRefGoogle Scholar
  5. 5.
    Chousterman BG, Arnaud M (2018) Is there a role for hematopoietic growth factors during sepsis? Front Immunol 9:1015CrossRefGoogle Scholar
  6. 6.
    Peng W, Xing Z, Yang J, Wang Y, Wang W, Huang W (2014) The efficacy of erythropoietin in treating experimental traumatic brain injury: a systematic review of controlled trials in animal models. J Neurosurg 121:653–664CrossRefGoogle Scholar
  7. 7.
    Ranjbaran M, Kadkhodaee M, Seifi B, Mirzaei R, Ahghari P (2018) Resuscitative therapy with erythropoietin reduces oxidative stress and inflammatory responses of vital organs in a rat severe fixed-volume hemorrhagic shock model. Gen Physiol Biophys 37:83–92CrossRefGoogle Scholar
  8. 8.
    Rocha J, Eduardo-Figueira M, Barateiro A, Fernandes A, Brites D, Pinto R, Freitas M, Fernandes E, Mota-Filipe H, Sepodes B (2015) Erythropoietin reduces acute lung injury and multiple organ failure/dysfunction associated to a scald-burn inflammatory injury in the rat. Inflammation 38:312–326CrossRefGoogle Scholar
  9. 9.
    Patel NS, Nandra KK, Thiemermann C (2012) Bench-to-bedside review: erythropoietin and its derivatives as therapies in critical care. Crit Care 16:229CrossRefGoogle Scholar
  10. 10.
    Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klausner MA, Corwin MJ, Group EPOCCT (2007) Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 357:965–976CrossRefGoogle Scholar
  11. 11.
    Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A, Bohlius J (2012) Erythropoietin or darbepoetin for patients with cancer. Cochrane Datab Syst Rev 12:CD003407Google Scholar
  12. 12.
    Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, Investigators C (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085–2098CrossRefGoogle Scholar
  13. 13.
    Fishbane S, Besarab A (2007) Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol CJASN 2:1274–1282CrossRefGoogle Scholar
  14. 14.
    Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(264–269):W264CrossRefGoogle Scholar
  15. 15.
    Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Cochrane Statistical Methods G (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928CrossRefGoogle Scholar
  16. 16.
    Lykissas MG, Korompilias AV, Vekris MD, Mitsionis GI, Sakellariou E, Beris AE (2007) The role of erythropoietin in central and peripheral nerve injury. Clin Neurol Neurosurg 109:639–644CrossRefGoogle Scholar
  17. 17.
    Abrishamkar S, Safavi M, Honarmand A (2012) Effect of erythropoietin on Glasgow Coma Scale and Glasgow Outcome Sale in patient with diffuse axonal injury. J Res Med Sci 17:51–56Google Scholar
  18. 18.
    Aloizos S, Evodia E, Gourgiotis S, Isaia EC, Seretis C, Baltopoulos GJ (2015) Neuroprotective effects of erythropoietin in patients with severe closed brain injury. Turk Neurosurg 25:552–558Google Scholar
  19. 19.
    Bai XF, Gao YK (2018) Recombinant human erythropoietin for treating severe traumatic brain injury. Medicine (Baltimore) 97:e9532CrossRefGoogle Scholar
  20. 20.
    Cariou A, Deye N, Vivien B, Richard O, Pichon N, Bourg A, Huet L, Buleon C, Frey J, Asfar P, Legriel S, Narcisse S, Mathonnet A, Cravoisy A, Dequin PF, Wiel E, Razazi K, Daubin C, Kimmoun A, Lamhaut L, Marx JS, de la Garanderie DP, Ecollan P, Combes A, Spaulding C, Barat F, Ben Boutieb M, Coste J, Chiche JD, Pene F, Mira JP, Treluyer JM, Hermine O, Carli P, Epo ACRSG (2016) Early high-dose erythropoietin therapy after out-of-hospital cardiac arrest: a multicenter, randomized controlled trial. J Am Coll Cardiol 68:40–49CrossRefGoogle Scholar
  21. 21.
    Corwin HL, Gettinger A, Rodriguez RM, Pearl RG, Gubler KD, Enny C, Colton T, Corwin MJ (1999) Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 27:2346–2350CrossRefGoogle Scholar
  22. 22.
    Corwin HL, Gettinger A, Pearl RG et al (2002) Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA J Am Med Assoc 288:2827–2835CrossRefGoogle Scholar
  23. 23.
    de Seigneux S, Ponte B, Weiss L, Pugin J, Romand JA, Martin PY, Saudan P (2012) Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study. BMC Nephrol 13:132CrossRefGoogle Scholar
  24. 24.
    Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ, Hutchison R, Mehrtens JE, Robinson JM, Schollum JB, Westhuyzen J, Celi LA, McGinley RJ, Campbell IJ, George PM (2010) Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 77:1020–1030CrossRefGoogle Scholar
  25. 25.
    Gabriel A, Kozek S, Chiari A, Fitzgerald R, Grabner C, Geissler K, Zimpfer M, Stockenhuber F, Bircher NG (1998) High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J Trauma 44:361–367CrossRefGoogle Scholar
  26. 26.
    Georgopoulos D, Matamis D, Routsi C, Michalopoulos A, Maggina N, Dimopoulos G, Zakynthinos E, Nakos G, Thomopoulos G, Mandragos K, Maniatis A, Critical Care Clinical Trials Greek G (2005) Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]. Crit Care 9:R508–R515CrossRefGoogle Scholar
  27. 27.
    Gerasimov L (2012) Use of erythropoietin in patients with injury and blood loss. General Reanimatol 8:11–17CrossRefGoogle Scholar
  28. 28.
    Li ZM, Xiao YL, Zhu JX, Geng FY, Guo CJ, Chong ZL, Wang LX (2016) Recombinant human erythropoietin improves functional recovery in patients with severe traumatic brain injury: a randomized, double blind and controlled clinical trial. Clin Neurol Neurosurg 150:80–83CrossRefGoogle Scholar
  29. 29.
    Luchette FA, Pasquale MD, Fabian TC, Langholff WK, Wolfson M (2012) A randomized, double-blind, placebo-controlled study to assess the effect of recombinant human erythropoietin on functional outcomes in anemic, critically ill, trauma subjects: the long term trauma outcomes study. Am J Surg 203:508–516CrossRefGoogle Scholar
  30. 30.
    Nichol A, French C, Little L, Haddad S, Presneill J, Arabi Y, Bailey M, Cooper DJ, Duranteau J, Huet O, Mak A, McArthur C, Pettila V, Skrifvars M, Vallance S, Varma D, Wills J, Bellomo R, Investigators E-T, Group ACT (2015) Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial. Lancet 386:2499–2506CrossRefGoogle Scholar
  31. 31.
    Nirula R, Diaz-Arrastia R, Brasel K, Weigelt JA, Waxman K (2010) Safety and efficacy of erythropoietin in traumatic brain injury patients: a pilot randomized trial. Crit Care Res Pract.  https://doi.org/10.1155/2010/209848 Google Scholar
  32. 32.
    Robertson CS, Hannay HJ, Yamal JM, Gopinath S, Goodman JC, Tilley BC, Epo Severe TBITI, Baldwin A, Rivera Lara L, Saucedo-Crespo H, Ahmed O, Sadasivan S, Ponce L, Cruz-Navarro J, Shahin H, Aisiku IP, Doshi P, Valadka A, Neipert L, Waguspack JM, Rubin ML, Benoit JS, Swank P (2014) Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial. JAMA J Am Med Assoc 312:36–47CrossRefGoogle Scholar
  33. 33.
    Silver M, Corwin MJ, Bazan A, Gettinger A, Enny C, Corwin HL (2006) Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial. Crit Care Med 34:2310–2316CrossRefGoogle Scholar
  34. 34.
    Springborg JB, Moller C, Gideon P, Jorgensen OS, Juhler M, Olsen NV (2007) Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial. Acta Neurochir (Wien) 149:1089–1101 (discussion 1101) CrossRefGoogle Scholar
  35. 35.
    Tseng MY, Hutchinson PJ, Richards HK, Czosnyka M, Pickard JD, Erber WN, Brown S, Kirkpatrick PJ (2009) Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. Clinical article. J Neurosurg 111:171–180CrossRefGoogle Scholar
  36. 36.
    van Iperen CE, Gaillard CA, Kraaijenhagen RJ, Braam BG, Marx JJ, van de Wiel A (2000) Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 28:2773–2778CrossRefGoogle Scholar
  37. 37.
    French CJ, Glassford NJ, Gantner D, Higgins AM, Cooper DJ, Nichol A, Skrifvars MB, Imberger G, Presneill J, Bailey M, Bellomo R (2017) Erythropoiesis-stimulating agents in critically ill trauma patients: a systematic review and meta-analysis. Ann Surg 265:54–62CrossRefGoogle Scholar
  38. 38.
    Mesgarpour B, Heidinger BH, Roth D, Schmitz S, Walsh CD, Herkner H (2017) Harms of off-label erythropoiesis-stimulating agents for critically ill people. Cochrane Datab Syst Rev 8:CD010969Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Intensive Care UnitSt John of God Hospital SubiacoPerthAustralia
  2. 2.School of MedicineUniversity of Western AustraliaPerthAustralia
  3. 3.Intensive Care UnitNoosa HospitalNoosavilleUSA
  4. 4.Fiona Stanley HospitalPerthAustralia
  5. 5.Department of AnaesthesiaRockingham General HospitalPerthAustralia
  6. 6.Intensive Care UnitFiona Stanley HospitalPerthAustralia

Personalised recommendations